TH.TO

Theratechnologies Inc. [TH.TO] Stock Forecast

Q: What is Theratechnologies Inc. stock symbol ?

Theratechnologies Inc. is a CA stock, located in Montreal of Qc and trading under the symbol TH.TO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

TH.TO Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Profit margins (-0.37%) are lower than the previous year (-0.29%)

TH.TO has less than 1 year of cash runway

Top 10 Correlated ETFs

TH.TO

Top 10 Correlated Stocks

TH.TO

In the News

TH.TO Financial details

Company Rating

Neutral

Market Cap

86.9M

Income

-23.96M

Revenue

81.76M

Book val./share

Cash/share

Dividend

Dividend %

Employees

103

Optionable

Shortable

Yes

Earnings

10 Jul 2024

P/E

-1.79

Forward P/E

PEG

0.35

P/S

0.65

P/B

-1.25

P/C

P/FCF

-5.13

Quick Ratio

0.33

Current Ratio

0.42

Debt / Equity

-2.83

LT Debt / Equity

-2.46

EPS (TTM)

-0.24

EPS next Y

EPS next Q

EPS this Y

82%

EPS next Y

EPS next 5Y

EPS last 5Y

31.66%

Revenue last 5Y

5.28%

Revenue Q/Q

12.45%

EPS Q/Q

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

-51%

ROE

84%

ROC

0.46%

Gross Margin

74%

Oper. Margin

-24%

Profit Margin

-37%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.22-5.84

52W High

-63.4%

52W Low

+83%

RSI

Rel Volume

0.2

Avg Volume

33.89K

Volume

6.78K

Perf Week

-9.85%

Perf Month

9.58%

Perf Quarter

44.09%

Perf Half Y

-21.79%

Beta

1.725

Volatility

0.03%, 0.18%

Prev Close

1.1%

Price

1.83

Change

1.67%

TH.TO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-11-30

Metric	2019-11-30	2020-11-30	2021-11-30	2022-11-30	2023-11-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.82	0.86	0.76	0.84	3.11
Net income per share	-0.23	-0.29	-0.34	-0.5	-0.91
Operating cash flow per share	-0.04	-0.18	-0.16	-0.15	-0.22
Free cash flow per share	-0.09	-0.18	-0.16	-0.16	-0.28
Cash per share	0.53	0.27	0.44	0.35	1.53
Book value per share	0.32	0.04	0.19	-0.24	-0.79
Tangible book value per share	-0.19	-0.37	-0.07	-0.39	-1.27
Share holders equity per share	0.32	0.04	0.19	-0.24	-0.79
Interest debt per share	0.99	0.79	0.68	0.77	2.63
Market cap	938.24M	713.9M	1.21B	830.69M	41.93M
Enterprise value	960.32M	756.54M	1.25B	873.55M	66.8M
P/E ratio	-53.66	-31.5	-38.22	-17.59	-1.75
Price to sales ratio	14.84	10.81	17.36	10.38	0.51
POCF ratio	-276.68	-52.67	-83.75	-56.54	-7.38
PFCF ratio	-133.79	-52.55	-82.8	-52.99	-5.59
P/B Ratio	37.78	221.43	68.27	-36.8	-2.01
PTB ratio	37.78	221.43	68.27	-36.8	-2.01
EV to sales	15.19	11.45	17.88	10.91	0.82
Enterprise value over EBITDA	24.01K	-82.43	-76.5	-32.17	-8.86
EV to operating cash flow	-283.2	-55.82	-86.26	-59.46	-11.76
EV to free cash flow	-136.93	-55.69	-85.28	-55.72	-8.91
Earnings yield	-0.02	-0.03	-0.03	-0.06	-0.57
Free cash flow yield	-0.01	-0.02	-0.01	-0.02	-0.18
Debt to equity	2.87	17.18	3.2	-2.96	-2.83
Debt to assets	0.61	0.55	0.48	0.72	0.76
Net debt to EBITDA	552	-4.65	-2.23	-1.58	-3.3
Current ratio	2.05	1.55	2.04	0.64	1.34
Interest coverage	-1.49	-3.35	-4.46	-6.14	-1.03
Income quality	0.27	0.6	0.46	0.31	0.24
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.13	0.19	0.21	0.22	0.19
Research and developement to revenue	0.17	0.27	0.4	0.46	0.37
Intangibles to total assets	0.34	0.32	0.2	0.16	0.16
Capex to operating cash flow	1.07	0	0.01	0.07	0.32
Capex to revenue	-0.06	0	0	-0.01	-0.02
Capex to depreciation	-0.48	0	-0.02	-0.08	-0.55
Stock based compensation to revenue	0.02	0.02	0.03	0.05	0.03
Graham number	1.28	0.53	1.22	1.63	4.03
ROIC	-0.11	-0.29	-0.33	-0.87	-0.28
Return on tangible assets	-0.22	-0.33	-0.33	-0.6	-0.37
Graham Net	-0.44	-0.7	-0.42	-0.67	-1.71
Working capital	39.04M	22.89M	46.83M	-40.91M	16M
Tangible asset value	-14.85M	-28.63M	-6.07M	-37.58M	-33.37M
Net current asset value	-16.54M	-32.11M	-9.54M	-42.46M	-35.34M
Invested capital	2.87	17.18	3.2	-2.96	-2.83
Average receivables	10.54M	11.65M	12.06M	11.64M	12.95M
Average payables	14.35M	15.31M	16.52M	14.21M	9.94M
Average inventory	16.01M	23.04M	27.14M	24.41M	12.88M
Days sales outstanding	58.41	72.86	57.13	56.28	60.49
Days payables outstanding	183.45	237.57	243.64	178.98	129.94
Days of inventory on hand	292.95	341.16	457.29	273.45	112.76
Receivables turnover	6.25	5.01	6.39	6.49	6.03
Payables turnover	1.99	1.54	1.5	2.04	2.81
Inventory turnover	1.25	1.07	0.8	1.33	3.24
ROE	-0.7	-7.03	-1.79	2.09	1.15
Capex per share	-0.05	0	0	-0.01	-0.07

Quarterly Fundamentals Overview

Last date of statement is 2023-11-30 for Q4

Metric	2022-11-30	2023-02-28	2023-05-31	2023-08-31	2023-11-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.23	0.21	0.18	0.86	0
Net income per share	-0.08	-0.11	-0.1	-0.03	0
Operating cash flow per share	-0.09	-0.03	-0.04	0.22	0
Free cash flow per share	-0.09	-0.04	-0.04	0.22	0
Cash per share	0.35	0.3	0.26	0.95	0
Book value per share	-0.24	-0.33	-0.43	-1.72	0
Tangible book value per share	-0.4	-0.48	-0.57	-2.25	0
Share holders equity per share	-0.24	-0.33	-0.43	-1.72	0
Interest debt per share	0.72	0.71	0.71	2.52	0
Market cap	829.63M	367.3M	345.34M	22.07M	0
Enterprise value	872.48M	413.26M	395.06M	65.34M	24.87M
P/E ratio	-26.16	-8.79	-8.62	-7.39	0
Price to sales ratio	38.73	18.45	19.68	1.06	0
POCF ratio	-100.63	-110	-96.95	4.14	0
PFCF ratio	-100.38	-103.14	-94.8	4.15	0
P/B Ratio	-36.76	-11.37	-8.32	-0.53	0
PTB ratio	-36.76	-11.37	-8.32	-0.53	0
EV to sales	40.73	20.76	22.51	3.13	1.06
Enterprise value over EBITDA	-189.42	-96.99	-58.02	60.28	10.16
EV to operating cash flow	-105.83	-123.77	-110.91	12.26	-6.06
EV to free cash flow	-105.56	-116.05	-108.44	12.3	-4.44
Earnings yield	-0.01	-0.03	-0.03	-0.03	0
Free cash flow yield	-0.01	-0.01	-0.01	0.24	0
Debt to equity	-2.96	-2.04	-1.61	-1.4	-2.83
Debt to assets	0.72	0.83	0.97	1.03	0.76
Net debt to EBITDA	-9.3	-10.79	-7.3	39.92	10.16
Current ratio	0.64	0.84	0.72	0.42	1.34
Interest coverage	-2.53	-2.33	-3.2	0.02	0.95
Income quality	1.04	0.32	0.36	-7.14	1.49
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.18	0.22	0.21	0.18	0.16
Research and developement to revenue	0.44	0.47	0.59	0.26	0.22
Intangibles to total assets	0.16	0.18	0.2	0.23	0.16
Capex to operating cash flow	0	0.07	0.02	0	0.37
Capex to revenue	0	-0.01	0	0	-0.06
Capex to depreciation	-0.02	-0.24	-0.09	-0.02	-2.6
Stock based compensation to revenue	0.04	0.03	0.04	0.02	0.02
Graham number	0.67	0.9	1	1.09	0
ROIC	-0.13	-0.16	-0.31	0	0.07
Return on tangible assets	-0.1	-0.16	-0.18	-0.02	-0.04
Graham Net	-0.67	-0.69	-0.72	-2.7	0
Working capital	-40.91M	-12.01M	-20.19M	-57.09M	16M
Tangible asset value	-37.58M	-46.58M	-55.06M	-54.56M	-33.37M
Net current asset value	-42.46M	-50.62M	-59.14M	-57.83M	-35.34M
Invested capital	-2.96	-2.04	-1.61	-1.4	-2.83
Average receivables	11.94M	11.36M	11.99M	11.36M	11.33M
Average payables	26.98M	23.48M	33.84M	32.03M	18.72M
Average inventory	21.41M	17.4M	12.14M	7.94M	6.39M
Days sales outstanding	51.86	46.94	69.76	39.34	52
Days payables outstanding	196.27	653.63	616.1	551.87	124.18
Days of inventory on hand	299.87	289.77	167.97	121.82	107.77
Receivables turnover	1.74	1.92	1.29	2.29	1.73
Payables turnover	0.46	0.14	0.15	0.16	0.72
Inventory turnover	0.3	0.31	0.54	0.74	0.84
ROE	0.35	0.32	0.24	0.02	0.13
Capex per share	0	0	0	0	0

TH.TO Frequently Asked Questions

What is Theratechnologies Inc. stock symbol ?

Theratechnologies Inc. is a CA stock , located in Montreal of Qc and trading under the symbol TH.TO

What is Theratechnologies Inc. stock quote today ?

Theratechnologies Inc. stock price is $1.83 today.

Is Theratechnologies Inc. stock public?

Yes, Theratechnologies Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 33.89K
Market Capitalization 86.9M
Employee 103
CEO Mr. Paul Lévesque
Headquarters Montreal,QC,CA
IPO Date 1996-08-06
Website https://www.theratech.com

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.